Good news! Cancer is history (soon)! Early results are very promising! Study was already published in November 2023.
"Scientists in Australia think they have discovered a better way to treat the deadliest and most aggressive form of breast cancer. ..."
"“This is an exciting development in the battle against triple negative breast cancer, which is the most aggressive form of the disease,” said Associate Professor Theresa Hickey, an internationally recognised breast cancer expert at the University of Adelaide’s Dame Roma Mitchell Cancer Research Laboratories. ...
The drug is designed to be taken orally and works by targeting a specific protein in the cancerous tumour called CDK9, which speeds up cell growth. By inhibiting this protein, it effectively stops cancer in its tracks. ...
“Our pre-clinical study shows that the drug was able to stop the tumour cells from multiplying but did not affect the normal cells in breast tissue taken from patients. It is still early days but based on this initial evidence, we believe inhibiting this protein could lead to a treatment for triple negative breast cancer and this new drug should be developed further,” said Associate Professor Hickey. ..."
From the abstract:
"Targeted therapy for triple-negative breast cancers (TNBC) remains a clinical challenge due to tumour heterogeneity. Since TNBC have key features of transcriptionally addicted cancers, targeting transcription via regulators such as cyclin-dependent kinase 9 (CDK9) has potential as a therapeutic strategy. Herein, we preclinically tested a new selective CDK9 inhibitor (CDDD11-8) in TNBC using cell line, patient-derived organoid, and patient-derived explant models. In vitro, CDDD11-8 dose-dependently inhibited proliferation (IC50 range: 281–734 nM), induced cell cycle arrest, and increased apoptosis of cell lines, which encompassed the three major molecular subtypes of TNBC. On target inhibition of CDK9 activity was demonstrated by reduced RNAPII phosphorylation at a CDK9 target peptide and down-regulation of the MYC and MCL1 oncogenes at the mRNA and protein levels in all cell line models. Drug induced RNAPII pausing was evident at gene promoters, with strongest pausing at MYC target genes. Growth of five distinct patient-derived organoid models was dose-dependently inhibited by CDDD11-8 (IC50 range: 272–771 nM), including three derived from MYC amplified, chemo-resistant TNBC metastatic lesions. Orally administered CDDD11-8 also inhibited growth of mammary intraductal TNBC xenograft tumours with no overt toxicity in vivo (mice) or ex vivo (human breast tissues). In conclusion, our studies indicate that CDK9 is a viable therapeutic target in TNBC and that CDDD11-8, a novel selective CDK9 inhibitor, has efficacy in TNBC without apparent toxicity to normal tissues."
New drug halts growth of aggressive breast cancer (University of Adelaide) A promising drug could lead to a new treatment for the most aggressive form of breast cancer, which affects thousands of women each year. A pre-clinical study led by the University of Adelaide found the new drug successfully inhibits the growth of triple negative breast cancer without any toxic side effects.
Fig. 1: CDDD11-8 inhibits proliferation, promotes cell cycle arrest, and increases apoptosis of TNBC cell lines in vitro.
No comments:
Post a Comment